Comparing Mortality in Patients with Atrial Fibrillation who are Receiving a Direct Oral Anticoagulant or Warfarin: A Meta-analysis of Randomized Trials.

CONCLUSION: Compared with warfarin therapy for stroke prevention in patients with AF, DOACs significantly reduce all-cause mortality, vascular mortality and bleeding mortality. This mortality benefit appears to be driven by the reduction in vascular- and bleeding-related mortality which, in turn, may be related to the reduction in intracranial bleeding. This article is protected by copyright. All rights reserved. PMID: 24986568 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24986568?dopt=Abstract

Source: Thrombosis and Haemostasis - July 1, 2014 Category: Hematology Authors: Liew A, O'Donnell M, Douketis J Tags: J Thromb Haemost Source Type: research